hero-line-left hero-line-top
For Life Sciences

Bringing together healthcare innovators

Syapse partners with life sciences companies who are committed to our mission of improving patient care and outcomes.

hero-line-bottom
hero-line-horizontal
temp-hero-icon

Work with us

Syapse seeks additional partners who are interested in building robust, meaningful collaborations focused on solving substantial challenges in oncology. We offer programs in the following areas:

  • Answer questions about real world clinical trends and the impact of precision medicine on outcomes and costs
  • Leverage regulatory-grade real-world data to accelerate FDA approvals
  • Access our network of providers for new programs to advance the practice of precision medicine
  • Patient population insights to improve trial efficiency and efficacy

Please contact us to inquire about potential partnerships.

As cancer remains one of the leading causes of death around the world, emerging software and data analytic tools are creating exciting opportunities to more rapidly develop and deliver targeted treatment options to patients. Our collaboration with Syapse supports this effort by leveraging real-world evidence to accelerate bringing new oncology treatments to market and empowers healthcare providers with more robust insights and decision-making tools to improve patient care.”
Mike Nohaile
Mike Nohaile
SVP of Strategy, Commercialization, and Innovation at Amgen

Resources

Let’s talk

If you’d like to learn more about Syapse, tell us a little about yourself and we will reach out as soon as possible. 

What's new

Syapse Announces Research Using Real-World Evidence at ASCO20 Virtual

SAN FRANCISCO – May 29, 2020 – Syapse today announced multiple research abstracts based on real-world data at the ASCO20 Virtual Annual Meet…

Read

Blog

Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses the findings from our collaborative research

Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer wh…

Read